• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR)

By: Bernstein Liebhard LLP via GlobeNewswire
July 28, 2025 at 08:00 AM EDT

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, inclusive.

Should You Join This Class Action Lawsuit?

  • Do you, or did you, own shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR)?
  • Did you purchase your shares between October 9, 2024 and July 10, 2025, inclusive?
  • Did you lose money in your investment in Capricor Therapeutics, Inc.?

If you purchased or acquired Capricor securities, and/or would like to discuss your legal rights and options please visit Capricor Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.

According to the lawsuit, Defendants made misrepresentations concerning Capricor’s four-year safety and efficacy data from the Phase 2 HOPE-2 trial study of deramiocel, the Company’s lead cell therapy candidate drug for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.

If you wish to serve as lead plaintiff for the Class, you must file papers by September 15, 2025. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
pallocco@bernlieb.com


Primary Logo

More News

View More
DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?
August 30, 2025
Via MarketBeat
Tickers DKS
Engines to AI: Cummins’ Surprising Growth Driver
August 30, 2025
Via MarketBeat
Topics Artificial Intelligence Earnings Energy
Tickers CMI
Smaller Industrials Names Seeing Surging Growth: Here's Why
August 30, 2025
Via MarketBeat
Topics Earnings
Tickers AZZ CAT DY PRIM XLI
MarketBeat Week in Review – 08/25 - 08/29
August 30, 2025
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers AVAV BJ COST CSCO EVTL MDB
Improving Fundamentals Drive New Buybacks for 3 Strong Performers
August 29, 2025
Via MarketBeat
Tickers DAVE GCT SFM
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap